Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $8 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $2 | $2 | $1 | $1 |
| Gross Profit | -$2 | $7 | -$1 | -$1 |
| % Margin | – | 81.8% | – | – |
| R&D Expenses | $106 | $97 | $85 | $74 |
| G&A Expenses | $36 | $42 | $26 | $23 |
| SG&A Expenses | $36 | $41 | $26 | $23 |
| Sales & Mktg Exp. | $0 | -$2 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $8 | -$10 |
| Operating Expenses | $143 | $138 | $111 | $97 |
| Operating Income | -$143 | -$140 | -$111 | -$97 |
| % Margin | – | -1,692.5% | – | – |
| Other Income/Exp. Net | $11 | $7 | $15 | -$3 |
| Pre-Tax Income | -$132 | -$132 | -$96 | -$99 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$132 | -$133 | -$96 | -$100 |
| % Margin | – | -1,608.8% | – | – |
| EPS | -0.73 | -0.76 | -0.61 | -0.63 |
| % Growth | 3.9% | -24.6% | 3.2% | – |
| EPS Diluted | -0.73 | -0.76 | -0.61 | -0.63 |
| Weighted Avg Shares Out | 182 | 175 | 157 | 157 |
| Weighted Avg Shares Out Dil | 182 | 175 | 157 | 157 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $15 | $10 | $10 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$139 | -$128 | -$92 | -$95 |
| % Margin | – | -1,556.2% | – | – |